Development of a technology platform able to achieve complete remission of Chronic Lymphocytic Leukemia (CLL) with little or no side effects for the users.
Technology platform for personalized treatments against CLL
Scientific and External Validation:
- Finalised all pre-clinical research on DOT-Cells® for CLL – in vitro and in vivo studies;
- Effective at eliminating cancer cells both in vitro and in vivo;
- Strong evidence that the therapy is indeed capable of preventing tumour spread (metastasis) in humans;
- No evidence of severe toxicity;
- Validated by several leading immune-oncologists and haematologists;
- The EMA confirmed potential significant benefit over all approved therapies.
More info at lymphact.com/